Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation

Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01113294

Enrollment

2040

Registered

2010-04-29

Start date

2009-01-31

Completion date

2013-12-31

Last updated

2010-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

To compare the efficacy of different procedures, identify the optimal procedure, ablation sites, ablation endpoints and post-operative anticoagulation strategy, establish the optimal treatment strategy for atrial fibrillation.

Interventions

PROCEDUREcatheter ablation

circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Atrial fibrillation recorded by ECG or Holter; 2. Age: 18 \ 75 years; 3. Patients who are willing to enroll in the trial

Exclusion criteria

1. Patients accompanied hyperthyroidism; 2. Patients with sever liver or renal dysfunction; 3. Patients with sever cardiac dysfunction; 4. Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure; 5. Patients with emboli in atrium; 6. Pregnant woman

Design outcomes

Primary

Measure	Time frame
recurrence of atrial arrhythmias (AF, AFL, AT)	1 month

Secondary

Measure	Time frame
Number of participants with all-cause death	1 month
severe blooding complications	1 month
cardio-cerebrovascular complications	1 month
Number of participants with cardiovascular death events	1 month

Countries

China

Contacts

Primary ContactCong-xin Huang, doctor

huangcongxin@yahoo.com.cn13907131546

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026